Detection of Circulating tumor cells (CTC) from Patients with Hepatocellular Carcinoma (HCC)

Overview

About this study

This study is being done to investigate if we can identify circulating tumor cell from the peripheral blood of patients with hepatocellular carcinoma using an investigational device, RareCyte system. The results of this test will be compared to the results of the FDA-approved CellSearch Test.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult, age 18 to 100
Patients with BLC C HCC with portal vein invasion or extrahepatic metastasis.

Exclusion Criteria:

Patient with significant anemia (Hemoglobin <7g/dL)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Lewis Roberts, M.B., Ch.B., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials